London, United Kingdom
AlphaBiomics, founded in 2018, is a biotechnology company headquartered in the United Kingdom. Operating at the intersection of health care and life sciences, it positions itself as "The Precision Medicine Company." The startup focuses on developing precision medicine solutions based on patients' gut microbiomes. This approach addresses the significant unmet medical need stemming from the current "one size fits all" methodology, which often leads to variable drug efficacy and safety responses.
With a mission to deliver safer and more effective drug therapies, AlphaBiomics aims to transform the clinical care paradigm. The company's strategic focus is on leveraging biotechnology to tailor medical treatments to individual patients, thus enhancing treatment outcomes across the disease spectrum.
To date, AlphaBiomics has secured a €100.00K grant investment, received in November 2018. The absence of prominent investors since then underscores the need for fresh capital injection to fuel its innovative endeavors and market penetration efforts.
